Cure of Acanthamoeba cerebral abscess in a liver transplant patient
β Scribed by Konrad Tang-Tat Fung; Amar Paul Dhillon; James E. McLaughlin; Sebastian B. Lucas; Brian Davidson; Keith Rolles; David Patch; Andrew K. Burroughs
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 344 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.21409
No coin nor oath required. For personal study only.
β¦ Synopsis
Acanthamoeba-related cerebral abscess and encephalitis are rare but usually fatal, being caused by free-living amoebic infections usually occurring in immunocompromised patients. In patients receiving transplants, a literature review showed that the infection is universally fatal. The diagnosis is often missed despite appropriate investigations including lumbar puncture, computerized tomography, and brain biopsy. We present the first reported liver transplant patient with Acanthamoeba cerebral abscess. The diagnosis was made in brain tissue removed at decompressive frontal lobectomy. He was successfully treated with a 3-month course of co-trimoxazole and rifampicin. There was no recurrence of the disease after 11 years of follow-up.
π SIMILAR VOLUMES
Among solid organ transplant (SOT) recipients, donor-seropositive/recipient-seronegative (DΟ©/RΟͺ) cytomegalovirus (CMV) status is associated with the highest risk of ganciclovir-resistant CMV disease, which has been reported for patients receiving oral ganciclovir but not valganciclovir prophylaxis.
Mycobacterium tuberculosis (MTB) causes substantial morbidity and mortality in liver transplant recipients. We examined the efficacy of isoniazid latent Mycobacterium tuberculosis infection (LTBI) treatment in liver transplant recipients and reviewed systematically all cases of active MTB infection
Mayo risk score, United Network for Organ Sharing (UNOS) status, Organ Sharing.